2898.Hk
The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and commercialization of diagnostic products and services.
Business. The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and commercialization of diagnostic products and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and commercialization of diagnostic products and services.
The company maintains a strong liquidity position, with a current ratio of 11.17, indicating that it has significantly more current assets than current liabilities. However, the company reported negative operating and free cash flows of -109.02 million and -119.79 million CNY, respectively, suggesting ongoing cash burn. The debt-to-equity ratio is low at 0.08, reflecting a conservative capital structure with minimal leverage.
Profitability metrics are negative, with a return on equity of -15.62% and a return on assets of -14.26%, indicating that the company is not generating returns for its shareholders or asset base. These figures are below the industry median for return on equity and return on assets, which are typically positive for firms in the biotechnology and medical research sector.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in the healthcare diagnostics space, where regulatory and reimbursement changes can significantly impact revenue.
The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent fiscal year. The absence of positive revenue growth, combined with negative operating and net income, suggests the company is in a development or expansion phase, where investment in R&D and operations is outpacing revenue generation.
Risk factors include the company's negative cash flows and profitability, which could lead to increased reliance on external financing. However, the dilution risk is currently low, as the number of shares outstanding has not changed between basic and diluted shares, and no immediate filing-based dilution flags were detected. The company's liquidity risk is also low, supported by a high current ratio and significant cash and equivalents of 78.99 million CNY.
Recent events include the company's continued investment in R&D and capital expenditures, with a capital expenditure of 49.26 million CNY. The company has not disclosed any major regulatory or legal events in the latest filings, and there are no immediate liquidity or dilution concerns based on the latest financial data.
- The company has a strong liquidity position with a current ratio of 11.17, but it is burning cash with negative operating and free cash flows.
- The company is not profitable, with negative return on equity and return on assets, which are below industry medians.
- The company's revenue is concentrated in a single business segment, increasing exposure to market-specific risks.
- The company is in a development or expansion phase, with no disclosed revenue growth and negative net income.
- The company has low dilution and liquidity risks, supported by a high current ratio and no immediate filing-based flags.
- The company is investing in R&D and capital expenditures, indicating a focus on long-term growth.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- 2898.HK Market data — financials · 2026-05-26
Ownership & reference
Leadership
- Feng ZhangExecutive Chairman of the Board